Allarity Therapeutics enters its Q1 2026 earnings call on May 22 having shed 13% over the past week, and the tension is straightforward: a clinical-stage biotech with no revenue, a binary pipeline, and a print arriving in days.
The stock closed at $1.35 on Friday, down 11% in a single session. That reverses a solid one-month bounce of roughly 13%. Peers in the micro-cap biotech space had a rough week too — ACET fell 10% over the same period and MBIO dropped 13% — so some of the pressure is sector-wide, though ALLR's day-on-day move was sharper than most.
Short positioning is modest, but it ticked up on the week. Short interest climbed 11% over seven days to just under 2% of the free float, a level that is notable only because it drifted higher into the earnings window after spending much of April declining from an April 10 peak near 3.5% of float. The borrow market is relaxed: cost to borrow has eased to around 6%, its lowest level in six weeks, and has come down roughly 14% over the past week alone. Borrow availability is ample — there is no sign of squeeze pressure anywhere in the lending data, and the ORTEX short score of 38.8 sits comfortably in the middle of the range, unchanged in direction over recent sessions.
The Street view on ALLR is thin and concentrated. Ascendiant Capital's Edward Woo raised his target to $9.75 from $9.50 in early April — the fourth consecutive raise since initiating coverage in mid-2025. That target, more than seven times the current price, reflects a net present value model on Stenoparib rather than a near-term commercial story. The bull case rests on the DRP-guided patient selection approach and the potential to unlock value in ovarian cancer and small cell lung cancer indications where PARP inhibitors have shown traction. The bear case is blunt: minimal revenue ($0.32 million for full-year 2025), net losses of $11.2 million, and total dependence on a single development asset in a competitive therapeutic class. The company raised $20.93 million in equity earlier in the year, which provides a runway, but dilution has been a recurring feature of the story. The factor profile adds little colour — scores on EPS surprise, sector rank, and short metrics all cluster near the 50th percentile, offering no strong directional signal.
Earnings history for ALLR shows wide swings in both directions. The company reported full-year 2025 results on March 30, and the stock barely moved — up under 2% on day one, recovering further over the following five sessions. The November 2025 print was the notable exception: the stock popped 18% on day one and held most of that gain, up 34% five days out. The release before that went the other way, falling 6% on the day. The pattern is consistent with a name where results function more as a catalyst for repositioning than a straightforward beat-or-miss dynamic.
With earnings set for May 22, the stock's behaviour through the end of this week — the degree to which the sell-off finds any footing or accelerates — will set the tone for how positioning enters the print.
See the live data behind this article on ORTEX.
Open ALLR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
